[1] |
方菲,谢淑华. 血清中肿瘤标志物联合检测在乳腺癌早期诊断中的研究[J]. 中国肿瘤临床与康复, 2014, 21(5): 540-541.
|
[2] |
丁芋友,姚德姣. 乳腺癌的治疗现状[J]. 湖南中医杂志, 2014, 30(6): 179-181.
|
[3] |
尹昆,赵桂华,刘俏俏, 等. 新型乳腺癌标志基因C35的研究进展[J]. 中国病原生物学杂志, 2011, 6(5): 391-394.
|
[4] |
Evans EE,Henn AD,Jonason A, et al.C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer[J]. Mol Cancer Ther, 2006, 5(11): 2919-2930.
|
[5] |
Rakha EA,El-Sayed ME,Powe DG, et al.Invasive lobular carcinoma of the breast:Response to hormonal therapy and outcomes[J]. Eur J Cancer, 2008, 44(1): 73-83.
|
[6] |
Arpino G,Bardou VJ,Clark GM, et al.Infiltrating lobular carcinoma of the breast:tumor characteristics and clinical outcome[J]. Breast Cancer Res, 2004, 6(3): 149-156.
|
[7] |
王颀,陈中扬. 乳腺癌早期诊断的现状与挑战[J/CD]. 中华乳腺病杂志 (电子版), 2007, 2(2): 5-7.
|
[8] |
Duffy MJ.Serum tumor markers in breast cancer:are they of clinical value[J]. Clin Chem, 2006, 52(3): 345-351.
|
[9] |
Gion M,Mione R,Leon AE, et al.CA27.29:a valuable marker for breast cancer management[J]. Eur J Cancer, 2001, 37(3): 355-363.
|
[10] |
张更华. 肿瘤标志物检测在乳腺癌分期诊断的应用价值[J]. 临床合理用药, 2009, 2(16): 62.
|
[11] |
张华,项明洁,毛顺露, 等. 三项肿瘤标志物联合检测在乳腺癌诊断中的价值[J]. 中国实验诊断学, 2011, 15(1): 96-98.
|
[12] |
Bartlett J,Mallon E,Cooke T. The clinical evaluation of HER-2 status:which test to use? [J]. J Pathol, 2003, 199(4): 411-417.
|
[13] |
Maurer-Stroh S,Eisenhaber F. Refinement and prediction of protein prenylation motifs[J]. Genome Biol, 2005, 6(6): R55.
|
[14] |
潘祥林,王鸿利. 诊断学的任务与发展方向[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 8-9.
|
[15] |
王刚平,张红,梁云爱, 等. β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及诊断意义[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 57-61.
|
[16] |
Yang CJ,Chang CF,Huang LY, et al.Resonance assignments of human C35 (C17orf37) protein, a novel tumor biomarker[J]. Biomol NMR Assign, 2010, 4(2): 191-193.
|